US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by iTeos Therapeutics Inc.

News headline image
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Therapeutics Announces Its Intention to Wind Down Operations
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos to Participate in Upcoming Investor Conferences
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos to Participate in Upcoming Investor Conferences
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Therapeutics Announces $120 Million Registered Direct Offering
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos to Participate in Upcoming Investor Conferences
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS
News headline image
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
Tickers ITOS